Patrick Cohen

844 citations

26 papers · 556 indexed · h-index 12

Impact in

Gastroenterology top 5%
- Gastroesophageal reflux and treatments
Oncology
- HER2/EGFR in Cancer Research

Papers in ⓘ

Oncology 18
- HER2/EGFR in Cancer Research 11
- Cancer Treatment and Pharmacology 6
- Vascular Tumors and Angiosarcomas 2
Pulmonary and Respiratory Medicine 12
- Advanced Breast Cancer Therapies 11

Co-authors: André Beaulieu (1 shared paper)D. Choquette (1 shared paper)M Nahir (1 shared paper)Jean‐Pierre Pelletier (1 shared paper)Boulos Haraoui (1 shared paper)Itzhak Rosner (1 shared paper)Michael Yaron (1 shared paper)A Taccoen (2 shared papers)
Journals: Journal of Clinical Oncology (6 papers)Cancer Research (4 papers)Clinical Cancer Research (1 paper)Alimentary Pharmacology & Therapeutics (1 paper)Nature Communications (1 paper)
Partner nations: France United States Spain

In The Last Decade

Patrick Cohen

24 papers receiving 529 citations

Peers

Countries citing papers authored by Patrick Cohen

Since Specialization

Citations

This map shows the geographic impact of Patrick Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Cohen more than expected).

Fields of papers citing papers by Patrick Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Cohen. The network helps show where Patrick Cohen may publish in the future.

Co-authors

The 25 scholars most cited alongside Patrick Cohen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Patrick Cohen Line = papers co-authored together Patrick Cohen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Efficacy and safety of diacerein in osteoarthritis of the knee: A double-blind, placebo-controlled trial Arthritis & Rheumatism ·Jean‐Pierre Pelletier, Michael Yaron, Boulos Haraoui, Patrick Cohen, M Nahir, D. Choquette, Irina Wigler, Itzhak Rosner, André Beaulieu, (unknown)	2000	122
2	Effect on Intragastric pH of a PPI with a Prolonged Plasma Half-Life: Comparison between Tenatoprazole and Esomeprazole on the Duration of Acid Suppression in Healthy Male Volunteers The American Journal of Gastroenterology ·Richard H. Hunt, David Armstrong, Cindy James, Sadat K. Chowdhury, Yuhong Yuan, Paola Fiorentini, A Taccoen, Patrick Cohen	2005	67
3	Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet Oncology ·Jean‐Yves Blay, Zsuzsanna Pápai, Anthony W. Tolcher, Antoîne Italiano, Didier Cupissol, Antonio López–Pousa, Sant P. Chawla, Emmanuelle Bompas, Nada Babović, Nicolas Penel, Nicolás Isambert, Arthur P. Staddon, Esma Saâda-Bouzid, Armando Santoro, Fábio Franke, Patrick Cohen, Solenn Le-Guennec, George D. Demetri	2015	58
4	Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors Clinical Cancer Research ·Cristiana Sessa, Patricia LoRusso, Anthony W. Tolcher, Françoise Farace, Nathalie Lassau, Angelo Delmonte, Antonio Braghetti, Rastislav Bahleda, Patrick Cohen, Marie Hospitel, Christine Veyrat‐Follet, Jean‐Charles Soria	2013	42
5	AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer Nature Communications ·Aditya Bardia, Sarat Chandarlapaty, Hannah M. Linden, Gary A. Ulaner, Alice Gosselin, Sylvaine Cartot‐Cotton, Patrick Cohen, Séverine Doroumian, Gautier Paux, Marina Celanovic, Vasiliki Pelekanou, Jeffrey E. Ming, Nils Ternès, Monsif Bouaboula, Joon Sang Lee, Anne-Laure Bauchet, Mario Campone	2022	40
6	Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells Cancer Discovery ·Mélissa Taylor, Fanny Billiot, Virginie Marty, Valérie Rouffiac, Patrick Cohen, Elodie Tournay, Paule Opolon, Fawzia Louache, Gilles Vassal, Corinne Laplace‐Builhé, Philippe Vielh, Jean‐Charles Soria, Françoise Farace	2012	37
7	AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Journal of Clinical Oncology ·Sara M. Tolaney, Arlene Chan, Katarína Petráková, Suzette Delaloge, Mario Campone, Hiroji Iwata, Parvin F. Peddi, Peter A. Kaufman, Elisabeth De Kermadec, Qianying Liu, Patrick Cohen, Gautier Paux, Lei Wang, Nils Ternès, Eric Boitier, Seock‐Ah Im	2023	37
8	A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870). Journal of Clinical Oncology ·Carlos Gomez‐Roca, Valentina Boni, Víctor Moreno, John C. Morris, Jean‐Pierre Delord, Emiliano Calvo, Kyriakos P. Papadopoulos, Olivier Rixe, Patrick Cohen, Alexia Tellier, Samira Ziti‐Ljajic, Anthony W. Tolcher	2016	36
9	AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer Therapeutic Advances in Medical Oncology ·Aditya Bardia, Javier Cortés, Sara A. Hurvitz, Suzette Delaloge, Hiroji Iwata, Zhi‐Ming Shao, Dheepak Kanagavel, Patrick Cohen, Qianying Liu, Sylvaine Cartot‐Cotton, Vasiliki Pelekanou, Joyce O’Shaughnessy	2022	25
10	Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three‐way crossover study Alimentary Pharmacology & Therapeutics ·A. B. R. Thomson, Patrick Cohen, Hervé Ficheux, P Fiorentini, Florence Domagala, M. Homerin, A Taccoen	2006	21
11	Infiltrated blue-gray plaques in a patient with leukemia. Chloroma (granulocytic sarcoma) Archives of Dermatology ·Patrick Cohen	1987	18
12	AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). Journal of Clinical Oncology ·Sarat Chandarlapaty, Hannah M. Linden, Patrick Neven, Katarína Petráková, Aditya Bardia, Peter Kabos, Sofía Braga, Valentina Boni, Alice Gosselin, Sylvaine Cartot‐Cotton, Séverine Doroumian, Marina Celanovic, Patrick Cohen, Gautier Paux, Mario Campone	2021	13
13	Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Primary Results From AMEERA-5 Journal of Clinical Oncology ·Javier Cortés, Sara A. Hurvitz, Joyce O’Shaughnessy, Suzette Delaloge, Hiroji Iwata, Hope S. Rugo, Patrick Neven, Dheepak Kanagavel, Patrick Cohen, Gautier Paux, Sylvaine Cartot‐Cotton, Maya Stefanova-Urena, Laure Deyme, Jihane Aouni, Bernard Sébastien, Aditya Bardia	2024	7
14	[Efficacy of diacerein on the symptoms and radiographic progression of osteoarthritis]. PubMed ·D Provvedini, Patrick Cohen	2002	7
15	Abstract P1-17-11: Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer Cancer Research ·Sarat Chandarlapaty, Hannah M. Linden, Patrick Neven, Katarína Petráková, Aditya Bardia, Peter Kabos, Sofía Braga, Valentina Boni, Alice Gosselin, Marina Celanovic, Patrick Cohen, Gautier Paux, Vasiliki Pelekanou, Nils Ternès, Joon Sang Lee, Mario Campone	2022	6
16	Two Patient Studies of a Companion Diagnostic Immuno-Positron Emission Tomography (PET) Tracer for Measuring Human CA6 Expression in Cancer for Antibody Drug Conjugate (ADC) Therapy Molecular Imaging ·Arutselvan Natarajan, Shyam Srinivas, E. Carmen Azevedo, Lacey Greene, Anne-Laure Bauchet, Erwan Jouannot, Anne-Sophie Lacoste-Bourgeacq, Isabelle Guizon, Patrick Cohen, Anne-Laure Naneix, Ohad Ilovich, Jordan Cisneros, Krithika Rupanarayan, Frederick T. Chin, Andrei Iagaru, Frederick M. Dirbas, Amer Karam, Sanjiv S. Gambhir	2020	5
17	A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors. Journal of Clinical Oncology ·Michael Ong, Gianluca Del Conte, Rastislav Bahleda, Joaquı́n Mateo, Silvia Damian, Antonella Perotti, Nathalie Lassau, Françoise Farace, Jimena Lovosgaldeano, Nina Tunariu, Marie Hospitel, Paola Mariani, Patrick Cohen, Giuseppe Capri, Jean‐Charles Soria, Luca Gianni, L Rhoda Molife, Cristiana Sessa	2013	3
18	264P AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) Annals of Oncology ·Sarat Chandarlapaty, Hannah M. Linden, Patrick Neven, Katarína Petráková, Aditya Bardia, Peter Kabos, Sofía Braga, Valentina Boni, Vasiliki Pelekanou, Nils Ternès, Alice Gosselin, Marina Celanovic, Patrick Cohen, Gautier Paux, Mario Campone	2021	3
19	Joint modeling of tumor dynamics and progression‐free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I–II trials CPT Pharmacometrics & Systems Pharmacology ·Marc Cerou, Hoai‐Thu Thai, Laure Deyme, Sophie Fliscounakis‐Huynh, Emmanuelle Comets, Patrick Cohen, Sylvaine Cartot‐Cotton, Christine Veyrat‐Follet	2024	2
20	A high-resolution human SNP linkage map Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) ·Tara C. Matise, Ravi Sachidanandam, Andrew G. Clark, Leonid Kruglyak, Ellen M. Wijsman, Buena Chui, Patrick Cohen, Claudio Toma, Margaret G. Ehm, Stephen Glanowski, Chundi He, Jeremy Heil, Ivy McMullen, Lincoln Stein, M.L. Wagner, Jeffrey D. Winick, Emily S. Winn-Deen, Howard M. Cann, Eric Lai, H. L. Holden	2002	2

About Patrick Cohen

Patrick Cohen is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Genetics, having authored 26 papers that have together received 556 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (11 papers), Advanced Breast Cancer Therapies (11 papers), Cancer Treatment and Pharmacology (6 papers), Breast Cancer Treatment Studies (3 papers), Cancer, Hypoxia, and Metabolism (3 papers), Angiogenesis and VEGF in Cancer (3 papers), Estrogen and related hormone effects (3 papers) and Vascular Tumors and Angiosarcomas (2 papers). The work is most often cited by research in Gastroenterology (72 citations), Oncology (209 citations), Cancer Research (96 citations), Rheumatology (91 citations) and Pharmacology (83 citations). Patrick Cohen has collaborated with scholars based in France, United States and Spain. Frequent co-authors include André Beaulieu, D. Choquette, M Nahir, Jean‐Pierre Pelletier, Boulos Haraoui, Itzhak Rosner, Michael Yaron, A Taccoen, Anthony W. Tolcher and Yuhong Yuan. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Alimentary Pharmacology & Therapeutics and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact